myAirvo2 Therapy by Fisher & Paykel

Enhancing Respiratory Care for Improved Health

Respiratory disorders affect a significant portion of the population, impacting their quality of life and overall health[1]. Fortunately, advancements in medical technology have led to the development of innovative treatments like myAirvo2 therapy, which provide substantial benefits for patients with respiratory conditions. In this blog post, we will explore myAirvo2 therapy, its indications, the types of respiratory disorders it helps with, the benefits it offers, and how it works. We will also discuss the use of myAirvo2 therapy with and without oxygen therapy, as well as provide Canadian statistics on the prevalence of respiratory disorders.

myAirvo2 therapy, also known as high-flow nasal cannula (HFNC) therapy, is a non-invasive respiratory treatment that delivers humidified and heated oxygen-enriched air to patients. It is primarily indicated for individuals with various respiratory conditions, including:

  • Chronic obstructive pulmonary disease (COPD): A progressive lung disease characterized by difficulty breathing, coughing, and excess mucus production.
  • Acute respiratory failure: A condition that occurs when the lungs fail to provide adequate oxygen to the bloodstream or remove carbon dioxide efficiently.
  • Asthma exacerbation: An acute worsening of asthma symptoms, such as wheezing, shortness of breath, and coughing.
  • Pneumonia: An infection that inflames the air sacs in one or both lungs, causing symptoms like cough, fever, and difficulty breathing.
  • Post-extubation respiratory support: Assistance for patients who have been weaned off mechanical ventilation but still require respiratory support.
  • Sleep-disordered breathing: Including conditions like obstructive sleep apnea (OSA), where patients experience repetitive episodes of partial or complete upper airway obstruction during sleep[2][3].

Respiratory disorders affect a considerable portion of the Canadian population. According to the latest available data, approximately 6.3% of Canadians aged 35 to 79 have been diagnosed with COPD, with a higher prevalence in men (7.5%) compared to women (5.2%)[1]. Additionally, asthma affects approximately 8.5% of the Canadian population, with the highest prevalence among children aged 0-14 years[4]. These statistics highlight the significant burden respiratory disorders pose to individuals and society as a whole.

myAirvo2 therapy provides several benefits for patients with respiratory conditions:

  • Improved oxygenation: The delivery of heated, humidified, and oxygen-enriched air helps improve oxygen levels in the blood, enhancing overall oxygenation and reducing symptoms associated with hypoxemia.
  • Enhanced secretion clearance: The humidification of inspired air by myAirvo2 therapy promotes better mucus clearance, reducing the risk of infection and improving lung function.
  • Comfortable and non-invasive: myAirvo2 therapy is well-tolerated by patients due to its comfortable and non-invasive delivery system, allowing for extended use without discomfort or pain.
  • Reduced work of breathing: By delivering oxygen at higher flow rates, myAirvo2 therapy can decrease the work of breathing for patients, reducing fatigue and improving respiratory efficiency.
  • Better sleep quality: For individuals with sleep-disordered breathing, myAirvo2 therapy can help alleviate symptoms, improve sleep quality, and reduce the risk of associated complications[3][5].

myAirvo2 therapy consists of a humidifier, an air/oxygen blender, a heated breathing circuit, and a nasal cannula. The system is designed to deliver a precisely regulated flow of warm, humidified, and oxygen-enriched air to the patient's respiratory system. The warmed and humidified air helps maintain optimal airway conditions, promoting effective gas exchange in the lungs[3].

The myAirvo2 system has adjustable flow rates, allowing healthcare professionals to tailor the therapy to meet individual patient needs. The heated circuit and nasal cannula prevent the airway from drying out, reducing discomfort and minimizing the risk of damage to the respiratory mucosa. For patients who require supplemental oxygen, the myAirvo2 system can be combined with an oxygen concentrator or cylinder, ensuring precise oxygen delivery[3].

myAirvo2 therapy can be used with or without supplemental oxygen, depending on the patient's needs. Patients requiring additional oxygen support can benefit from myAirvo2 therapy combined with oxygen therapy, as it allows for precise oxygen concentration delivery at higher flow rates. This is especially important for patients with severe respiratory conditions or those experiencing acute exacerbations.

For individuals not on oxygen therapy, myAirvo2 therapy can still provide significant benefits. The heated, humidified, and oxygen-enriched air helps maintain optimal respiratory conditions, improving oxygenation, secretion clearance, and reducing the work of breathing. This makes myAirvo2 therapy an effective and versatile treatment option for a wide range of respiratory disorders.

myAirvo2 therapy, or high-flow nasal cannula therapy, is a non-invasive respiratory treatment that offers numerous benefits for individuals with respiratory disorders. Its ability to provide heated, humidified, and oxygen-enriched air promotes better oxygenation, secretion clearance, and respiratory comfort. Whether used with or without supplemental oxygen, myAirvo2 therapy is a valuable tool in improving the quality of life for patients with conditions such as COPD, acute respiratory failure, asthma exacerbation, pneumonia, post-extubation respiratory support, and sleep-disordered breathing.

If you would like to learn more about myAirvo2 therapy, contact our team, we would love to hear from you. Our experienced healthcare professionals can provide personalized guidance and support, helping you make informed decisions about your respiratory care.

Rebel Sleep Institute

Reference List:

  1. Government of Canada. (2021). Canadian Chronic Obstructive Pulmonary Disease (COPD) Surveillance Program: Updated statistics 2020.
  2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2022). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.
  3. Vianello, A., Arcaro, G., & Gallan, F. (2018). High-flow nasal cannula oxygen therapy in acute respiratory failure. Critical Care, 22(1), 201.
  4. Canadian Lung Association. (2021). Asthma facts and statistics.
  5. Chen, L., Zhang, J., Pan, J., Xia, J., Cao, J., & Yan, Y. (2020). Effect of high-flow nasal cannula versus conventional oxygen therapy for patients with asthma exacerbation: A systematic review and meta-analysis. Journal of Critical Care, 57, 78-85.